ReproCELL Incorporated (4978.T)
JPY 147.0
(2.08%)
JPY 147.0
(2.08%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.93 Billion JPY | -53.51% |
| 2022 | -1.91 Billion JPY | 25.27% |
| 2021 | -2.56 Billion JPY | -1.61% |
| 2020 | -2.52 Billion JPY | 44.04% |
| 2019 | -4.5 Billion JPY | -11.73% |
| 2018 | -4.03 Billion JPY | -15.52% |
| 2017 | -3.49 Billion JPY | -4.91% |
| 2016 | -3.32 Billion JPY | -0.3% |
| 2015 | -3.31 Billion JPY | -16.9% |
| 2014 | -2.83 Billion JPY | 44.25% |
| 2013 | -5.09 Billion JPY | -2954.35% |
| 2012 | -166.67 Million JPY | 6.38% |
| 2011 | -178.03 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.51 Billion JPY | 14.6% |
| 2023 Q3 | -2.35 Billion JPY | -12.74% |
| 2023 Q4 | -2.93 Billion JPY | -25.01% |
| 2023 Q1 | -3.04 Billion JPY | -59.16% |
| 2023 Q2 | -2.08 Billion JPY | 31.57% |
| 2023 FY | -2.93 Billion JPY | -53.51% |
| 2022 Q3 | -2.39 Billion JPY | 10.18% |
| 2022 Q1 | -4.19 Billion JPY | -63.89% |
| 2022 FY | -1.91 Billion JPY | 25.27% |
| 2022 Q4 | -1.91 Billion JPY | 20.11% |
| 2022 Q2 | -2.66 Billion JPY | 36.45% |
| 2021 FY | -2.56 Billion JPY | -1.61% |
| 2021 Q1 | -2.9 Billion JPY | -15.14% |
| 2021 Q2 | -4.04 Billion JPY | -39.21% |
| 2021 Q4 | -2.56 Billion JPY | 23.26% |
| 2021 Q3 | -3.33 Billion JPY | 17.39% |
| 2020 Q3 | -2.53 Billion JPY | 33.0% |
| 2020 Q4 | -2.52 Billion JPY | 0.4% |
| 2020 FY | -2.52 Billion JPY | 44.04% |
| 2020 Q1 | -4.87 Billion JPY | -8.21% |
| 2020 Q2 | -3.77 Billion JPY | 22.5% |
| 2019 FY | -4.5 Billion JPY | -11.73% |
| 2019 Q3 | -3.11 Billion JPY | 13.99% |
| 2019 Q4 | -4.5 Billion JPY | -44.8% |
| 2019 Q1 | -3.79 Billion JPY | 5.84% |
| 2019 Q2 | -3.61 Billion JPY | 4.73% |
| 2018 FY | -4.03 Billion JPY | -15.52% |
| 2018 Q4 | -4.03 Billion JPY | 21.62% |
| 2018 Q3 | -5.14 Billion JPY | -18.06% |
| 2018 Q2 | -4.35 Billion JPY | -42.22% |
| 2018 Q1 | -3.06 Billion JPY | 12.22% |
| 2017 Q3 | -3.63 Billion JPY | 3.49% |
| 2017 FY | -3.49 Billion JPY | -4.91% |
| 2017 Q1 | -3.85 Billion JPY | -15.93% |
| 2017 Q4 | -3.49 Billion JPY | 3.87% |
| 2017 Q2 | -3.76 Billion JPY | 2.46% |
| 2016 FY | -3.32 Billion JPY | -0.3% |
| 2016 Q3 | -2.58 Billion JPY | 4.41% |
| 2016 Q4 | -3.32 Billion JPY | -28.6% |
| 2016 Q2 | -2.7 Billion JPY | 10.18% |
| 2016 Q1 | -3.01 Billion JPY | 9.16% |
| 2015 Q2 | -2.96 Billion JPY | -8.08% |
| 2015 FY | -3.31 Billion JPY | -16.9% |
| 2015 Q1 | -2.74 Billion JPY | 3.22% |
| 2015 Q4 | -3.31 Billion JPY | 5.98% |
| 2015 Q3 | -3.52 Billion JPY | -18.87% |
| 2014 Q3 | -3.08 Billion JPY | 6.03% |
| 2014 Q4 | -2.83 Billion JPY | 7.86% |
| 2014 Q1 | -5.18 Billion JPY | -1.93% |
| 2014 Q2 | -3.27 Billion JPY | 36.83% |
| 2014 FY | -2.83 Billion JPY | 44.25% |
| 2013 FY | -5.09 Billion JPY | -2954.35% |
| 2013 Q1 | -2.08 Billion JPY | 0.0% |
| 2013 Q2 | -2.63 Billion JPY | -26.02% |
| 2013 Q3 | -2.68 Billion JPY | -2.18% |
| 2013 Q4 | -5.09 Billion JPY | -89.41% |
| 2012 FY | -166.67 Million JPY | 6.38% |
| 2011 FY | -178.03 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 495.695% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -159.189% |
| GNI Group Ltd. | -17.93 Billion JPY | 83.611% |
| Linical Co., Ltd. | -4.46 Billion JPY | 34.15% |
| Trans Genic Inc. | -221.16 Million JPY | -1228.874% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 33.112% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 38.642% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 305.021% |
| AnGes, Inc. | -3.79 Billion JPY | 22.611% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -598.433% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 111.8% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -489.99% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -530.23% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | -8.607% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -55.654% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -199.25% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 13.481% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -184.089% |
| Kidswell Bio Corporation | 343.58 Million JPY | 955.399% |
| PeptiDream Inc. | 3.29 Billion JPY | 189.279% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -202.188% |
| Ribomic Inc. | -2.09 Billion JPY | -39.972% |
| SanBio Company Limited | -3.78 Billion JPY | 22.447% |
| Healios K.K. | -2.19 Billion JPY | -34.204% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -211.057% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | -12.0% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -107.405% |
| StemRIM | -8.41 Billion JPY | 65.053% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 37.246% |
| FunPep Company Limited | -1.79 Billion JPY | -63.884% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | -37.565% |
| Stella Pharma Corporation | -1.11 Billion JPY | -162.556% |
| TMS Co., Ltd. | -3.44 Billion JPY | 14.727% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 47.098% |
| Cuorips Inc. | -5.56 Billion JPY | 47.149% |
| K Pharma,Inc. | -3.26 Billion JPY | 10.022% |
| Takara Bio Inc. | -32.2 Billion JPY | 90.873% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -344.665% |
| StemCell Institute Inc. | -2.83 Billion JPY | -3.606% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -42.235% |
| CellSeed Inc. | -2.01 Billion JPY | -46.073% |